Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110096 | 0.86 | ALDH1A1 (0.82) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3587631 | 0.84 | ADORA3 (0.82) | KMT2AMEN1ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL15086878 | 0.83 | ALOX5 (0.74) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15064976 | 0.83 | MEN1 (1.00) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7146818 | 0.82 | ADORA3 (0.56) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL544732 | 0.82 | ALDH1A1 (0.62) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6286094 | 0.80 | ALDH1A1 (0.73) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14960379 | 0.79 | ALDH1A1 (0.74) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16607177 | 0.79 | NPC1 (0.83) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL25063308 | 0.78 | KMT2A (0.56) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2797885-B1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-2797885-B1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-2797885-A1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8530461-B2 | Azetidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-10 | — | — | US | disclosed |
| US-8530461-B2 | Azetidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-10 | — | — | US | disclosed |
| US-8530461-B2 | Azetidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-10 | — | — | US | disclosed |
| US-20130172312-A1 | Azetidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172312-A1 | Azetidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172312-A1 | Azetidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| WO-2013098373-A1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013098373-A1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172312-A1 | Azetidine Derivatives | GPR119, LIPE, LPL | KMT2A 2063/4885MEN1 2095/4885CYP1A2 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.